


PHARMACEUTICAL 2022

RVL Pharmaceuticals plc Rank 279 of 475







PHARMACEUTICAL 2022

RVL Pharmaceuticals plc Rank 279 of 475



The relative strengths and weaknesses of RVL Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RVL Pharmaceuticals plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 184% points. The greatest weakness of RVL Pharmaceuticals plc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 196% points.

The company's Economic Capital Ratio, given in the ranking table, is -161%, being 115% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	59,379
Cost of Goods Sold	3,618
Intangible Assets	83,057
Liabilities, Current	20,108
Liabilities, Non-Current	592
Other Assets	2,234
Other Compr. Net Income	3,929
Other Expenses	8,195
Other Liabilities	47,237
Other Net Income	23,785
Property and Equipment	0
Research and Development	6,930
Revenues	17,501
Selling, General and Administrative Expense	87,463

Output Variable	Value in 1000 USD
Assets	144,670
Liabilities	67,937
Expenses	106,206
Stockholders Equity	76,733
Net Income	-64,920
Comprehensive Net Income	-62,956
Economic Capital Ratio	-161%